Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway

Xinbo Wu, Haiyang Yu, Haichao Zhou, Zihua Li, Hui Huang, Fajiao Xiao, Shaochen Xu, Yunfeng YangJournal of Cellular and Molecular Medicine 2020 · DOI

TL;DR

This study investigates the anti-cancer potential of proanthocyanidin B2 (PB2), a natural compound, against osteosarcoma (OS), a challenging bone cancer. Researchers found that PB2 effectively inhibits OS cell proliferation and promotes apoptosis by suppressing the PI3K/AKT signaling pathway, offering a promising avenue for new OS therapies.

What Problem Does This Paper Address?

Osteosarcoma (OS) is the most common primary bone cancer in children and adolescents, but its long-term survival rates remain low, largely due to chemotherapy resistance and metastasis. Existing treatments, while improving, often come with significant toxic side effects. This creates an urgent need for novel, more effective, and less toxic therapeutic agents. Natural compounds have emerged as a promising area for drug discovery, and this paper focuses on proanthocyanidin B2 (PB2), a polyphenol found in foods like grapes and cranberries, to explore its potential as an anti-cancer agent for OS.

Methods

The researchers employed a multi-faceted approach to evaluate PB2's effects:

  • In vitro studies:
    • Cell Viability and Proliferation: CCK-8 assays and colony formation assays were used to measure how PB2 affects the growth and survival of various OS cell lines (143B, MNNG, SJSA, MG-63) and a normal osteoblast cell line (hFOB1.19).
  • Apoptosis Analysis: Flow cytometry with Annexin V-FITC and propidium iodide staining was used to quantify the percentage of apoptotic cells. Western blotting and qRT-PCR were employed to assess the expression levels of key apoptosis-related proteins (e.g., Bax, Bcl-2, cleaved Caspase-3, cleaved Caspase-9, PARP) and proliferation markers (PCNA).
  • Mitochondrial Membrane Potential (MMP) Assay: JC-1 staining and flow cytometry were used to detect changes in MMP, a critical indicator of early apoptosis.
  • Signaling Pathway Analysis: qRT-PCR and Western blotting were used to investigate the impact of PB2 on the PI3K/AKT signaling pathway, examining the expression of PI3K, p-PI3K, AKT, and p-AKT.
  • Caspase Inhibition: The role of caspases in PB2-induced apoptosis was explored by using a caspase inhibitor (Z-VAD-FMK) in combination with PB2.
  • PI3K/AKT Pathway Activation: To confirm the role of the PI3K/AKT pathway, a PI3K agonist (740Y-P) was used in combination with PB2 to observe its effects on proliferation and apoptosis.
  • In vivo studies:
    • Xenograft Mouse Model: A subcutaneous xenograft mouse model was established by injecting 143B OS cells into nude mice. Mice were then treated with PB2 or a control.
  • Tumor Growth Monitoring: Tumor volume and mouse body weight were measured regularly.
  • Histological Analysis: Immunohistochemistry staining (H&E, Ki-67, TUNEL) was performed on tumor tissues to assess proliferation and apoptosis. Major organs were also examined for potential toxicity.

Datasets

Not discussed in the paper. The study utilized established human osteosarcoma cell lines (143B, MNNG, SJSA, MG-63) and a normal human osteoblast cell line (hFOB1.19). In vivo experiments used BALB/c nude mice.

Key Insights and Ideas

  • PB2 as a Selective Anti-Cancer Agent: PB2 demonstrated a significant inhibitory effect on OS cell proliferation while having minimal impact on normal osteoblast cells, suggesting a degree of selectivity that is highly desirable for cancer therapeutics.
  • Dual Action: Inhibition and Induction: PB2 not only stops cancer cells from multiplying but also actively triggers their self-destruction (apoptosis). This two-pronged attack is more effective than targeting a single process.
  • Mitochondrial Pathway Activation: The disruption of mitochondrial membrane potential by PB2 is a key event leading to the release of apoptotic factors, highlighting the activation of the intrinsic apoptotic pathway.
  • PI3K/AKT Pathway as a Key Target: The study strongly implicates the PI3K/AKT pathway as a central mediator of PB2's anti-cancer effects. Suppressing this pathway appears to be the primary mechanism by which PB2 exerts its influence.
  • In Vivo Efficacy Confirmed: The promising in vitro results were successfully translated to an in vivo model, where PB2 significantly inhibited tumor growth without causing overt toxicity to major organs, reinforcing its therapeutic potential.

Key Results

  • PB2 significantly inhibited the proliferation of OS cell lines (143B, MNNG, SJSA, MG-63) in a dose- and time-dependent manner, with IC50 values for 143B and MNNG at 48 hours being 57.5 µmol/L and 55 µmol/L, respectively.
  • PB2 treatment led to a dose-dependent increase in OS cell apoptosis, with apoptosis rates reaching up to 62.0% in 143B cells and 58.9% in MNNG cells at 90 µmol/L.
  • PB2 treatment resulted in a decrease in the expression of the anti-apoptotic protein Bcl-2 and an increase in pro-apoptotic proteins Bax, cleaved Caspase-3, cleaved Caspase-9, and PARP.
  • PB2 disrupted mitochondrial membrane potential, leading to the release of cytochrome c and AIF into the cytoplasm.
  • PB2 significantly reduced the mRNA and protein levels of PI3K and AKT, key components of the PI3K/AKT pathway.
  • Activating the PI3K/AKT pathway with 740Y-P partially reversed the anti-proliferative and pro-apoptotic effects of PB2.
  • In vivo, PB2 treatment significantly inhibited the growth of OS xenografts in mice, with no significant impact on body weight or major organ histology.

Limitations and Future Work

The authors acknowledge several limitations:

  • Short-term In Vivo Study: The in vivo experiments were conducted over a three-week period. Future work should explore whether PB2 can prolong median survival time or reduce the risk of tumor recurrence over longer durations.
  • Lack of Clinical Trials: The study did not include clinical trials in human patients. This is a crucial next step to determine the clinical efficacy of PB2 for osteosarcoma.
  • Bioavailability Concerns: PB2's poor bioavailability, due to low water solubility and instability, is a significant challenge for its therapeutic application. The authors suggest future research could focus on strategies to enhance bioavailability, such as structural modifications, using bioactive carrier systems (liposomes, nanoparticles), or co-administration with absorption enhancers.

Despite these limitations, the study provides a strong foundation for further investigation into PB2 as a potential therapeutic agent for osteosarcoma, particularly by targeting the PI3K/AKT pathway.

Summary updated

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. The long-term survival rate of OS patients is stubbornly low mainly due to the chemotherapy resistance. We therefore aimed to investigate the antitumoral effects and underlying mechanisms of proanthocyanidin B2 (PB2) on OS cells in the current study. The effect of PB2 on the proliferation and apoptosis of OS cell lines was assessed by CCK-8, colony formation, and flow cytometry assays. The target gene and protein expression levels were measured by qRT-PCR and Western blotting. A xenograft mouse model was established to assess the effects of PB2 on OS proliferation and apoptosis in vivo. Results from in vitro experiments showed that PB2 inhibited the proliferation and induced apoptosis of OS cells, and also increased the expression levels of apoptosis-related proteins. Moreover, PB2 induced OS cell apoptosis through suppressing the PI3K/AKT signalling pathway. The in vivo experiments further confirmed that PB2 could inhibit OS tumour growth and induce its apoptosis. Taken together, these results suggested that PB2 inhibited the proliferation and induced apoptosis of OS cells through the suppression of the PI3K/AKT signalling pathway.
BibTeX
@article{wu2020proanthocyanidin,
  author = {Xinbo Wu and Haiyang Yu and Haichao Zhou and Zihua Li and Hui Huang and Fajiao Xiao and Shaochen Xu and Yunfeng Yang},
  title = {{Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2020},
  doi = {10.1111/jcmm.15818},
}
Figure